News

Astellas and Sony Enter ADC Platform Collaboration

May 17, 2023

Astellas and Sony will collaborate to discover a novel ADC platform for use in oncology.

CATTI Starts Up CGT Training Center at University of Guelph

May 17, 2023

CATTI has launched an in-person training site at the University of Guelph in Ontario, Canada, for training personnel in cell and gene therapy manufacturing.

Mursla Bio Discovers New Biomarker Approach in Precision Medicine

May 17, 2023

The new method was developed to isolate tissue-specific EVs from the blood in addition to using a workflow to analyze their diverse multi-omics content.

EMA Issues Drug Safety Reminders

May 17, 2023

The agency’s safety committee is reviewing hydroxyprogesterone medicines and issuing a reminder on safety issues regarding fluoroquinolone antibiotics.

EMA Guidance Looks to Prevent Drug Shortages

May 17, 2023

The agency has published guidance on good practices for securing the supply of medicines.

EMA Publishes Annual Report for 2022

May 17, 2023

The report outlines highlights from the agency’s medicines evaluations and milestones for 2022.

SeraNovo and AstraZeneca Collaborate on Future Research Projects

May 17, 2023

This deal would help the companies merge to work on future projects and conduct research together.

FTC Sues to Block Amgen’s $27.8 Billion Acquisition of Horizon Therapeutics

May 16, 2023

In a brief, the Federal Trade Commission cited concerns about the acquisition resulting in an increased monopoly on Amgen’s newly acquired thyroid eye disease and chronic refractory gout treatments.

Bright Path Laboratories to Collaborate in NSF Engines Development Program

May 16, 2023

The NSF-sponsored program aims to help partners collaborate to create opportunities for significant economic, societal, and technological opportunities for growth in their regions.

BiOneCure Therapeutics and Nanjing Leads Biolabs Partner to Develop ADCs for Solid Tumors

May 16, 2023

Under the collaboration, BiOneCure Therapeutics and Nanjing Leads Biolabs intend to develop a range of innovative antibody-drug conjugates for treating solid tumors.